SciELO - Scientific Electronic Library Online

 
vol.30 issue6Virological surveillance and antiviral resistance of human influenza virus in Argentina, 2005-2008HIV transmitted drug resistance in adult and pediatric populations in Panama author indexsubject indexarticles search
Home Page  

Revista Panamericana de Salud Pública

Print version ISSN 1020-4989

Rev Panam Salud Publica vol.30 n.6 Washington Dec. 2011

http://dx.doi.org/10.1590/S1020-49892011001200024 

ORIGINAL RESEARCH

 

Prevalence and patterns of HIV transmitted drug resistance in Guatemala

 

Prevalencia y patrones de farmacorresistencia transmitida del VIH en Guatemala

 

 

Santiago Avila-RíosI; Carlos R. Mejía-VillatoroII; Claudia García-MoralesI; Maribel Soto-NavaI; Ingrid EscobarII; Ricardo MendizabalII; Amalia GirónII; Leticia GarcíaII; Gustavo Reyes-TeránI

ICentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico. Send correspondence to: Gustavo Reyes-Terán, gustavo.reyesteran@gmail.com
IIClínica de Enfermedades Infecciosas, HospitalRoosevelt,Guatemala City, Guatemala

 

 


ABSTRACT

OBJECTIVE: To assess human immunodeficiency virus (HIV) diversity and the prevalence of transmitted drug resistance (TDR) in Guatemala.
METHODS: One  hundred  forty-five  antiretroviral  treatment-naïve  patients  referred  to  the Roosevelt  Hospital  in  Guatemala  City  were  enrolled  from  October  2010  to  March  2011. Plasma HIV pol sequences were obtained and TDR was assessed with the Stanford algorithm and the World Health Organization (WHO) TDR surveillance mutation list.
RESULTS: HIV subtype B was highly prevalent in Guatemala (96.6%, 140/145), and a 2.8% (4/145) prevalence of BF1 recombinants and 0.7% (1/145) prevalence of subtype C viruses were  found.  TDR  prevalence  for  the  study  period  was  8.3%  (12/145)  with  the  Stanford database algorithm (score > 15) and the WHO TDR surveillance mutation list. Most TDR cases were associated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) (83.3%, 10/12);  a  low  prevalence  of  nucleoside  reverse  transcriptase  inhibitors  and  protease  inhibitors was observed in the cohort (< 1% for both families). Low selection of antiretroviral drug resistance  mutations  was  found,  except  for  NNRTI-associated  mutations.  Major  NNRTI mutations such as K101E, K103N, and E138K showed higher frequencies than expected in ART-naïve populations. Higher literacy was associated with a greater risk of TDR (odds ratio 4.14, P = 0.0264).
CONCLUSIONS: This study represents one of the first efforts to describe HIV diversity and TDR prevalence and trends in Guatemala. TDR prevalence in Guatemala was at the intermediate level. Most TDR cases were associated with NNRTIs. Further and continuous TDR surveillance is necessary to gain more indepth knowledge about TDR spread and trends in Guatemala and to optimize treatment outcomes in the country.

Key words: HIV;  drug  resistance,  viral;  molecular  epidemiology;  epidemiologic  surveillance; Guatemala.


RESUMEN

OBJETIVO: Evaluar la diversidad del virus de la inmunodeficiencia humana (VIH) y la prevalencia de la farmacorresistencia transmitida en Guatemala.
MÉTODOS: Entre octubre del 2010 y marzo del 2011 se incluyeron en el estudio 145 pacientes no tratados anteriormente con antirretrovirales, derivados al Hospital Roosevelt en la Ciudad de Guatemala. Se obtuvieron las secuencias pol a partir del VIH plasmático y se evaluó la farmacorresistencia transmitida con el algoritmo de Stanford y la lista de mutaciones para la vigilancia de la farmacorresistencia transmitida de la Organización Mundial de la Salud (OMS).
RESULTADOS: El subtipo B del VIH fue sumamente prevalente en Guatemala (96,6%, 140/145), y se encontró una prevalencia de formas recombinantes BF1 de 2,8% (4/145) y una prevalencia del subtipo C del virus de 0,7% (1/145). La prevalencia de la farmacorresistencia transmitida durante el período de estudio fue de 8,3% (12/145) según el algoritmo de la base de datos de Stanford (puntuación > 15) y la lista de mutaciones para la vigilancia de la farmacorresistencia transmitida de la OMS. En la mayoría de los casos, la farmacorresistencia transmitida se asoció con los inhibidores de la transcriptasa inversa no análogos de nucleósidos (ITINN) (83,3%, 10/12); en la cohorte se observó una baja prevalencia asociada con los inhibidores de la transcriptasa inversa análogos de nucleósidos y con los inhibidores de la proteasa (< 1% para ambas familias de fármacos). Se encontró una baja selección de mutaciones causantes de farmacorresistencia debidas a los antirretrovirales, excepto en las mutaciones asociadas a los ITINN. Las mutaciones importantes relacionadas con los ITINN, como K101E, K103N y E138K, mostraron frecuencias más elevadas que las esperadas en las poblaciones vírgenes de tratamiento antirretroviral. En las personas con un nivel de escolaridad más elevado se encontró un mayor riesgo de farmacorresistencia transmitida (razón de posibilidades 4,14; P = 0,0264).
CONCLUSIONES: Este estudio representa uno de los primeros intentos de describir la diversidad del VIH, y la prevalencia de la farmacorresistencia transmitida y sus tendencias en Guatemala. La prevalencia de la farmacorresistencia transmitida en Guatemala presentó un nivel intermedio y en la mayoría de los casos se asoció con los ITINN. Se necesita una vigilancia más intensa y sostenida de la farmacorresistencia transmitida para conocer más exhaustivamente su grado de diseminación y sus tendencias en Guatemala, al igual que para optimizar los resultados del tratamiento antirretroviral en el país.

Palabras clave: VIH; farmacorresistencia viral; epidemiología molecular; vigilancia epidemiológica; Guatemala.


 

 

Extensive use of antiretroviral (ARV) drugs has led to increasing transmission of human immunodeficiency virus (HIV) variants with drug resistance mutations that can be maintained in individuals before initiation of treatment (1–9), reducing the efficacy of first-line ARV therapy (ART) (10). In resource-limited countries with recent introduction of broad access to ART, a relatively low prevalence of transmitted drug resistance (TDR) is expected, especially considering that most patients in this setting are starting on potent ART regimens (11). However, the lack of information on TDR prevalence and trends in many of these countries is alarming. In the past 5–10 years, most governments of Latin American and Caribbean countries have made efforts to implement programs to provide broad access to ART. As this strategy is cost– benefit advantageous and is the most visible among government responses to the epidemic, universal access to ART has become a priority goal in most countries in the region, while access to clinical attention, prevention programs, and laboratory monitoring of patients under treatment are neglected (12). TDR surveillance will generate important information to guide first-line ART selection, support education and prevention programs, and promote the rational use of ARV drugs by clinicians and policy makers (11, 13–15).

This study reports the first results of a large collaborative effort between Mexico and the countries of Central America to assess HIV TDR and viral diversity in the Mesoamerican region, focusing on Guatemala. ART was introduced in Guatemala by 2001 in hospitals managed by the Ministry of Public Health. From the 60 000 individuals in the country expected to live with HIV, more than 10 360 are reported to be receiving ART and 24 000 more are in need of ART according to World Health Organization (WHO) 2010 guidelines (16). Approximately 25% of patients using ART are treated in the Roosevelt Hospital in Guatemala City, a third-level, university hospital receiving patients from all over the country. From 2001 to 2007, first-line ART regimens were composed of zidovudine or stavudine + lamivudine + efavirenz (EFV) or nevirapine (NVP). From 2007, first-line ART regimens were changed to tenofovir disoproxil fumarate + emtricitabine + EFV or NVP. The use of protease inhibitors is reserved for second-line regimens and for pregnant women. Additionally, from all the patients using ART, 83% were reported to remain under ART after 12 months in 2009 (16). Considering this scenario, TDR prevalence and patterns in Guatemala are not known. This study reports TDR data on 145 ARV drugnaïve patients enrolled in 2010 and 2011.

 

METHODS

Patients

Newly diagnosed and follow-up ART-naïve HIV patients were enrolled in an observational study from October 2010 to March 2011 at the Roosevelt Hospital in Guatemala City. No exclusion criteria were applied except for known exposure to ARV drugs. Being a reference health center, the Roosevelt Hospital receives nearly 40% of patients from places outside Guatemala City, mainly from the southern Pacific Coast and the western regions of the country, including the departments of Escuintla, Santa Rosa, Suchitepequez, Retalhuleu, and San Marcos. After giving written, informed consent, patients donated a single peripheral blood sample, collected in vacuum tubes with ethylene-diaminetetraacetic acid (BD, San Jose, California, United States of America) for molecular assays and in Cyto-Chex BCT tubes (Streck, Omaha, Nebraska, United States) for immunophenotypic flow-cytometry assays. Demographic data were collected through direct application of a questionnaire before sample donation. All blood samples were sent via air courier and processed at the National Institute of Respiratory Diseases in Mexico City within 48 hours after collection. Plasma viral load assays, CD4+ T cell counts, HIV genotyping, and TDR analyses were performed for each patient. Results were sent to the Roosevelt Hospital for patient clinical follow-up. This study was revised and accepted by the Ethics Committees of the National Institute of Respiratory Diseases and the Roosevelt Hospital and was conducted according to the principles of the Declaration of Helsinki.

HIV sequencing and genotypic drug resistance testing

A fragment of the viral pol gene including the whole protease and 334 codons of the reverse transcriptase was bulk-sequenced from plasma HIV RNA, using a ViroSeq HIV-1 genotyping system (Celera Diagnostics, Alameda, California, United States), according to the manufacturer's specifications. Sequences were obtained with a model 3730 genetic analyzer (Applied Biosystems, Foster City, California, United States), assembled, and manually edited with ViroSeq v2.8 software.

Genotypic drug resistance analyses were carried out with the Stanford HIV drug resistance database algorithm, using the HIVdb program (17, 18). The presence of resistance was defined according to Stanford score (SS) ranges as follows: 0–9, susceptible; 10–14, potential low-level resistance; 15–29, low-level resistance; 30–59, intermediate resistance; 60 or higher, high-level resistance. All samples were analyzed at the same time using the last program update available (v6.0.11). Additionally, genotypic drug resistance was assessed by using the drug resistance mutation list for HIV TDR surveillance proposed and periodically updated by WHO (19). The combination of these two genotypic resistance interpretation systems provides a sound understanding of ARV drug resistance in the epidemiological setting of HIV TDR.

HIV subtyping and phylogenetic analyses

HIV subtyping was performed with the REGA subtyping tool v2.0 (20, 21), available online. Neighbor joining and maximum likelihood trees were built to confirm subtyping, using the software Mega 5.0, and recombination was confirmed with the RIP HIV recombination identification program (22), available online.

Statistical analyses

Chisquare or Fisher's exact tests were used to determine associations among patients' demographic variables and TDR risk. Odds ratios were calculated for each variable. Student's t tests were used to compare clinical variables and age in the TDR and susceptible groups.

 

RESULTS

TDR prevalence and patterns in 145 ART-naïve HIV-infected Guatemalan individuals, predominantly from Guatemala City, the southern Pacific Coast, and western regions of the country, were prospectively assessed. The protease/ reverse transcriptase HIV region was amplified successfully for all participating individuals. The Guatemalan cohort presented a median CD4+ T cell count of 303 cells per μL of blood (Table 1) with 46.2% (67/145) of patients diagnosed with CD4+ T cell counts < 200 cells per μL and 11.7% (17/145) with < 50 cells per μL. More than 44% of patients enrolled were female and the mean age at enrolment was 37.3 years (Table 1). Self-reported men who have sex with men (MSM) represented 14.8% (12/81) of the males enrolled.

Of the 145 HIV sequences analyzed, 140 (96.6%) belonged to subtype B. The remaining sequences (4/145, 2.8%) corresponded to BF1 recombinant forms and subtype C viruses (1/145, 0.7%). All non-B viruses were associated with heterosexual transmission.

A global TDR prevalence of 8.3% (12/145) to any ARV drug was found for the study period, based on SS values with a threshold of 15 (at least low-level ARV drug resistance). This definition of TDR was comparable to the one based on the WHO TDR surveillance mutation list (19), applicable for TDR surveillance (Table 2). The use of these two resistance definitions is informative as the Stanford algorithm considers polymorphic and minor mutations that, if accumulated, can result in some degree of ARV drug resistance, and the WHO mutation list provides a universal system for ARV drug resistance surveillance. Also, the Stanford algorithm would detect viruses (SS 10–14) that, although they are likely to be fully susceptible to ARV drugs, may contain mutations that could indicate previous exposure to the ARV class of the drug (23) (Table 2).

 

 

With the Stanford algorithm, the prevalence of TDR resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) was the most prevalent (10/145, 6.9%), while TDR to nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors was low (each at 1/145, 0.7%) (Table 2). High-level ARV drug resistance (SS ≥ 60) was observed only for NNRTIs (4/145, 2.8%) (Table 2, Figure 1). TDR to multiple drug classes was not observed in the Guatemalan cohort.

Overall, the presence of ARV drug resistance-associated mutations in the Guatemalan cohort was low (Table 3). TDR cases occurred almost exclusively for NNRTIs, with a third of the individuals with TDR showing high-level resistance to delavirdine, EFV, and NVP (Figure 1).

 

 

It was not possible to apply the WHO TDR threshold method for TDR surveillance (11, 24) because of the small numbers of patients under 25 years of age required for this analysis. Further TDR surveillance will allow the enrolment of adequate numbers of patients who fulfil the inclusion criteria required for this estimation.

Most NNRTI high-level TDR cases were associated with the presence of the reverse transcriptase K103N mutation (3/4), while most intermediate-level TDR cases presented a combination of the K101E and E138K/Q mutations (4/6) (Table 4). The single TDR cases found for the NRTI and protease inhibitor families were related to the presence of the reverse transcriptase K219K/Q and the protease L23I mutations, respectively (Table 4).

Univariate analyses showed no differences in age or clinical variables (i.e., viral load and CD4+ T cell counts) between subjects with and without TDR (Table 1). Interestingly, a greater probability of presenting TDR was found for individuals with higher literacy (primary school or none versus secondary school or higher; odds ratio 4.14, P = 0.0264) (Table 1). However, this result should be interpreted with care, as possible selection bias may exist with a larger proportion of individuals living in Guatemala City represented in the cohort. No differences associated with HIV transmission risk factor, marital status, or employment situation were found for TDR risk in the Guatemalan cohort.

 

DISCUSSION

This study presents the first results of a large collaborative effort between Mexico and Central American countries to describe HIV diversity and TDR prevalence in the Mesoamerican region, focusing on Guatemala. A cohort of ART-naïve, HIV-infected Guatemalan individuals referred to the Roosevelt Hospital was formed. The cohort reflected the previously observed male focalization of the infection and late presentation of HIV patients to medical care in the Guatemalan setting (16, 25). Nevertheless, a large proportion of females was observed in the study cohort, which most likely can be explained by an enrolment bias, as active HIV screening in the Gyneco-Obstetrics Service of the Roosevelt Hospital has been in place since 2002 for ambulatory patients and since 2006 in the emergency room (26). Interestingly, heterosexual transmission was the dominant risk factor for HIV infection, with only 14.8% of men identifying themselves as MSM. This observation could reflect the highly prevalent stigmatization of the infection and the characteristic machismo of many Latin American countries (27).

Remarkably, nearly 3% and 1% of the circulating viruses were subtyped as BF1 recombinant forms and subtype C viruses, respectively. This result is interesting, as recent observations in neighboring Mexico by this study group have shown a prevalence of < 0.15% of non-B viruses (unpublished data). These contrasting observations could reflect the existence of unique patterns of HIV transmission in Guatemala, which, further addressed, could yield important information on HIV epidemiological history in the country and provide HIV transmission and phylogenetic clustering information useful for HIV prevention and management in the country.

An intermediate global TDR level was found for the Guatemalan cohort. This TDR level is comparable to the one observed in some industrialized countries (1, 4, 6, 28). Analyses showed that more than 80% of TDR cases were associated with NNRTIs, with a very low prevalence of TDR to NRTIs and protease inhibitors (< 1% in both cases). This observation is consistent with the broad use of EFV/NVP-containing ARV regimens since 2001 in Guatemala. Moreover, this study showed evidence of low levels of selection of resistance mutations by ARV drugs in the study cohort, except for the case of NNRTI-associated mutations (Table 3). Remarkably, the K101E mutation was observed in 3.5% of Guatemalan patients, while the expected prevalence in ART-naïve populations is 0.2% (23). Similarly, the K103N, K103R, and E138K mutations, observed in 2.1%, 4.1%, and 2.8% of Guatemalan patients, respectively, are expected to be present in 0.8%, 2.0%, and 0.1% of ART-naïve populations (23). However, it is important to keep in mind that late detection of HIV disease is characteristic in most Latin American countries. As nearly half of the individuals enrolled in this study were diagnosed with < 200 CD4+ T cells per μL of blood, these results reflect TDR levels characteristic of individuals infected a few years in the past. Although high levels of adherence to ART have been reported for the Guatemalan setting (29), the differentially higher prevalence of NNRTI TDR in the Guatemalan cohort compared with TDR in other ARV drug families strongly suggests the existence of ARV drug selective pressure and will have to be taken into account in HIV management in order to improve treatment outcomes by supplying information to support education and prevention programs and to promote the rational use of ARV drugs by clinicians and policy makers in the country.

Higher literacy levels were associated with higher risk of TDR in the study cohort. Whether this observation reflects a selection bias in the Guatemalan cohort or a possible behavioral trend needs to be assessed further. Nevertheless, it is possible that this observation reflects a tendency of the MSM group to present higher literacy levels than the heterosexual population that attends the Roosevelt Hospital. Also, although the Roosevelt Hospital receives individuals from all over the country, more than half are known to reside in Guatemala City (26). These individuals usually have better access to education and also higher exposure to HIV and ART. Associations of other demographic and clinical variables cannot be discarded and need to be assessed further with larger cohorts.

This study represents one of the first efforts to describe HIV diversity and TDR prevalence and trends in Guatemala. It shows the existence of intermediate TDR levels in the Guatemalan setting. Most TDR cases were associated with NNRTIs, which is consistent with the broad use of this ARV drug family in treatment regimens in the country and with the low genetic barrier of these ARV drugs for the development of resistance. Although enrolment bias could exist, the present cohort is highly representative of the population seeking medical care at the most important HIV referral center in the country. Further and continuous TDR surveillance, as well as larger cohorts, will be necessary to gain more indepth knowledge of TDR spread and trends in Guatemala and to support HIV management and treatment outcomes in the country.

 

Acknowledgments

The authors thank all patients of the Guatemalan cohort for their participation in this study, Zeidy Arenas and Silvia del Arenal for their logistic assistance, Edna Rodriguez and Mario Preciado for CD4+ T cell count assays, Ramón Hernandez and Carolina Demeneghi for viral load assays, and Sandra Zamora for her administrative support. G.R.T., C.R.M.V., and S.A.R. conceived the study; S.A.R. wrote the manuscript; G.R.T., C.R.M.V., and S.A.R. critically revised the manuscript; C.G.M. and M.S.N. processed samples, performed genotyping tests, built and managed the patient database, and performed sequence alignments and resistance analyses; I.E., R.M., L.G., and A.G. were in charge of logistics of patient enrolment and sample shipment at the Roosevelt Hospital, contributed to analysis and interpretation of data, and revised the manuscript. This work was supported by the Mexican Government (Comisión de Equidad y Género de la H. Cámara de Diputados), Fundación Mexico Vivo and Instituto de Ciencia y Tecnología del Distrito Federal (ICyTDF, PIRIVE09-18). The authors have no competing interests.

 

REFERENCES

1. UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study, UK Register of HIV Seroconverters. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS. 2007;21(8):1035–9.         [ Links ]

2. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother. 2007;59(6):1047–56.         [ Links ]

3. Callegaro A, Svicher V, Alteri C, Lo Presti A, Valenti D, Goglio A, et al. Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008. Infect Genet Evol. 2011;11(3):624–32.         [ Links ]

4. Cardoso LP, Queiroz BB, Stefani MM. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naive patients from Central West Brazil. J Clin Virol. 2009;46(2):134–9.         [ Links ]

5. Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis. 2007;20(1):22–32.         [ Links ]

6. Hattori J, Shiino T, Gatanaga H, Yoshida S, Watanabe D, Minami R, et al. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res. 2010;88(1):72–9.         [ Links ]

7. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24(8):1203–12.         [ Links ]

8. Jayaraman GC, Archibald CP, Kim J, Rekart ML, Singh AE, Harmen S, et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr. 2006;42(1):86–90.         [ Links ]

9. Wong KH, Chan WK, Yam WC, Chen JH, Alvarez-Bognar FR, Chan KC. Stable and low prevalence of transmitted HIV type 1 drug resistance despite two decades of antiretroviral therapy in Hong Kong. AIDS Res Hum Retroviruses. 2010;26(10):1079–85.         [ Links ]

10.  Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363–71.         [ Links ]

11. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13(Suppl 2):1–13.         [ Links ]

12. Soto-Ramírez LE. HIV/AIDS in Latin America. Science. 2008;321(5888):465.         [ Links ]

13. Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT. The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 2008;49(2):196–204.         [ Links ]

14. Shafer RW, Rhee SY, Bennett DE. Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther. 2008;13(Suppl 2): 59–68.         [ Links ]

15. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev. 2008;10(2):67–84.         [ Links ]

16. Joint United Nations Programme on HIV/ AIDS. UNAIDS report on the global AIDS epidemic 2010. Geneva: UNAIDS; 2010. Available from: http://www.unaids.org/globalreport/Global_report.htm Accessed 14 March 2011.         [ Links ]

17. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608–18.         [ Links ]

18. Stanford University, Stanford HIV drug resistance database. HIVdb program. Genotypic resistance interpretation algorithm. Stanford: Stanford University, Stanford HIV drug resistance database; 2006. Available from: http://sierra2.stanford.edu/sierra/servlet/JSierra Accessed 7 March 2011.         [ Links ]

19. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724.         [ Links ]

20.  Katholieke Universiteit Leuven, HIV Bioinformatics Africa. REGA HIV-1 & 2 automated subtyping tool (version 2.0). Leuven, Belgium: REGA Institute, Katholieke Universiteit; 2006. Available from: http://www.bioafrica.net/ subtypetool/html/subtypinghiv.html Accessed 7 March 2011.         [ Links ]

21.  de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics. 2005;21(19):3797–800.         [ Links ]

22.  Los Alamos National Laboratory. Los Alamos HIV database. RIP HIV recombinant identification program. Los Alamos, New Mexico: Los Alamos National Laboratory; 2011. Available from: http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html Accessed 7 March 2011.         [ Links ]

23.  Stanford University. HIV drug resistance data-base. Stanford: Stanford University; 2006. Available from: http://www.hivdb.stanford.edu/ Accessed 7 March 2011.         [ Links ]

24. Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, Peeters M, et al. World Health Organization/HIVResNet drug resistance laboratory strategy. Antivir Ther. 2008;13(Suppl 2):49–57.         [ Links ]

25. Cohen J. HIV/AIDS: Latin America and Caribbean. Mexico and Central America. Science. 2006;313(5786):477.         [ Links ]

26. Clínica de Enfermedades Infecciosas. Hospital Roosevelt. Guatemala City: Clínica de Enfermedades Infecciosas, Hospital Roosevelt; 2011. Available from: http://infecciosashr.org/ Accessed 14 March 2011.         [ Links ]

27. Cohen J. HIV/AIDS: Latin America and Caribbean. Overview: the overlooked epidemic. Science. 2006;313(5786):468–9.         [ Links ]

28.  Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009;200(10):1503–8.         [ Links ]

29. Campbell JI, Ruano AL, Samayoa B, Estrado Muy DL, Arathoon E, Young B. Adherence to antiretroviral therapy in an urban, free-care HIV clinic in Guatemala City, Guatemala. J Int Assoc Physicians AIDS Care (Chic). 2010; 9(6):390–5.         [ Links ]

 

 

Manuscript received on 9 April 2011. Revised version accepted for publication on 31 October 2011.